1 / 5

Y. Nagata * , M. Hiraoka # , T. Shibata, H. Onishi , M. Kokubo ,

Stereotactic body radiation therapy for T1N0M0 non-small cell lung cancer. First report for inoperable population of a phase II trial by Japan Clinical Oncology Group (JCOG-0403). Y. Nagata * , M. Hiraoka # , T. Shibata, H. Onishi , M. Kokubo ,

bien
Download Presentation

Y. Nagata * , M. Hiraoka # , T. Shibata, H. Onishi , M. Kokubo ,

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Stereotactic body radiation therapy for T1N0M0 non-small cell lung cancer. First report for inoperable population of a phase II trial by Japan Clinical Oncology Group (JCOG-0403) Y. Nagata*,M. Hiraoka#, T. Shibata, H. Onishi, M. Kokubo, K. Karasawa, Y. Shioyama, R. Onimaru,E. Kunieda, S. Ishikura Radiation Therapy Study Group of Japan Clinical Oncology Group *Study Coordinator, #Primary Investigator ASTRO, Boston, Oct. 28-31, 2012.

  2. Stereotactic body radiation therapy (SBRT) delivers very targeted beams of radiation to a small area over a few days • SBRT is less invasive than surgery • SBRT is considered to work against T1N0M0 lung cancers • First report for operable population was presented in ASTRO 2010. • This presentation is the first report for inoperable population.

  3. First clinical trial to study SBRT for both inoperable & operable stage IA lung cancers • From 2004 to 2008, 104 patients from 15 institutions with early-stage inoperable non-small cell lung cancer were studied • Patients underwent 4 times daily radiotherapy over the course of four to eight days • Each treatment is non-invasive and painless, much like receiving an X-ray

  4. Patients followed for almost three years (37 months) after treatment • Overall survival rate for patients three years after SBRT was 60 percent • Patients reported only mild side effects from the treatment • Patients with inoperable early lung cancer should consider this treatment

  5. Conv RT vs. SBRT * In all eligible patients (n=100)

More Related